Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Neutral Rating from Wedbush

Wedbush reiterated their neutral rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL - Free Report) in a research report released on Friday morning,Benzinga reports. Wedbush currently has a $4.00 price objective on the stock.

A number of other brokerages also recently commented on ZNTL. UBS Group lowered their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Wells Fargo & Company decreased their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research note on Thursday, January 30th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $8.24.

Zentalis Pharmaceuticals Stock Down 5.3 %

Zentalis Pharmaceuticals stock traded down $0.09 during mid-day trading on Friday, reaching $1.51. 206,874 shares of the company's stock were exchanged, compared to its average volume of 1,527,462. The company has a fifty day moving average of $2.02 and a 200-day moving average of $2.84. The company has a market cap of $108.08 million, a P/E ratio of -0.60 and a beta of 1.75. Zentalis Pharmaceuticals has a twelve month low of $1.51 and a twelve month high of $16.27.

Remove Ads

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.09. The company had revenue of $26.90 million during the quarter. Equities research analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Insider Transactions at Zentalis Pharmaceuticals

In related news, Director Jan Skvarka purchased 60,000 shares of the company's stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the transaction, the director now directly owns 149,551 shares of the company's stock, valued at approximately $257,227.72. The trade was a 67.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Ingmar Bruns acquired 20,000 shares of the stock in a transaction that occurred on Thursday, February 6th. The stock was purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the transaction, the insider now owns 36,629 shares in the company, valued at $83,514.12. The trade was a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.60% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC acquired a new position in Zentalis Pharmaceuticals during the third quarter worth $75,000. Martingale Asset Management L P acquired a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at approximately $91,000. Capstone Investment Advisors LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter worth approximately $48,000. Verition Fund Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 172.1% in the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock worth $5,536,000 after acquiring an additional 951,500 shares during the period. Finally, PDT Partners LLC increased its stake in Zentalis Pharmaceuticals by 166.0% in the 3rd quarter. PDT Partners LLC now owns 107,159 shares of the company's stock valued at $394,000 after purchasing an additional 66,868 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.